---
title: Fabry Exercise Intolerance Study
nct_id: NCT05413876
overall_status: UNKNOWN
sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
study_type: OBSERVATIONAL
primary_condition: Fabry Disease
countries: Netherlands
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05413876.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05413876"
ct_last_update_post_date: 2023-08-24
last_seen_at: "2026-05-12T06:49:26.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Fabry Exercise Intolerance Study

**Official Title:** Fabry Exercise Intolerance Study (FEISTY)

**NCT ID:** [NCT05413876](https://clinicaltrials.gov/study/NCT05413876)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Conditions:** Fabry Disease, Fabry Disease, Cardiac Variant
- **Start Date:** 2021-10-10
- **Completion Date:** 2024-01-02
- **CT.gov Last Update:** 2023-08-24

## Brief Summary

Patients and healthy controls will undergo cardiopulmonary exercises and testing of the muscles strength to gain additional understanding of exercise intolerance as Fabry disease (FD) manifestation. An additional needle muscle biopsy may be performed. Tissue analysis from this biopsy will include evaluation of the lipidomics profile and mitochondrial function. Results of the tests and any potential exercise intolerance will be compared against healthy, age-, sex- and BMI-matched volunteers. The hypothesis is that patients with FD will have reduced exercise capacity due to changes in skeletal and cardiac muscle energy metabolism.

## Detailed Description

Background: Fabry disease (FD) is an inherited, highly variable and slowly progressive X linked disorder, which predominantly affects vascular endothelium, the heart, kidneys and the brain. Exercise intolerance is a complaint expressed by the majority of patients, at all stages of the disease. The exact cause, extent and development over time of exercise intolerance in FD in insufficiently understood. This limits preventive measures and adequate treatment.

Hypothesis: 1) The development of energy metabolism in skeletal and cardiac muscle in FD is disturbed early on in disease development and this progresses as the disease worsens, resulting in reduced exercise capacity. 2) Intermittent CPX is an objective and sensitive tool to grade the level of exercise tolerance in FD patients and yields specific outcome parameters that can be used in future intervention studies.

Primary objectives: 1) To study the presence and extent of exercise intolerance in male, female FD patients with classical FD and men with non-classical FD, in different stages of the disease. 2) To determine the aetiology of exercise intolerance in FD. Secondary objectives: 1) To determine whether the exercise test protocol used in this study can be used as a clinical outcome measure in future intervention studies. 2) To investigate difference in the time-relation between V'O2 and circulatory, ventilatory and metabolic variables during intermittent exercise between FD patients groups (potentially providing an indication of the source of possibly slowed V'O2 kinetics).

Methods: This study will consist of two screening visits, one testing procedure visit, and an optional second visit for all subjects enrolled in the study. During the first testing visit two cardiopulmonary exercise (CPX) test will be performed. During the CPX tests gas exchange, ventilation, blood pressure and cardiac output will be measured and exhaustion level monitored. Before and after the tests a blood sample will be taken. The upper leg muscle strength and the leg muscle size will be assessed. In order to detect alterations in skeletal muscle energy metabolism, a needle biopsy of the upper leg muscle will be taken during the second optional study visit. In the biopsy specimen, lipidomics profile, electronic microscopic characteristics of muscle tissue and mitochondrial function will be assessed.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* FD patients: Men and women with a definite known diagnosis of FD.
* Healthy controls: Healthy control subjects (men and women) with an age of 18 years of older.

Exclusion Criteria:

FD patients:

* Pregnancy
* Recent acute myocardial infarct (\<6 months)
* Uncontrolled arrhythmia/severe conduction disorder (atrial fibrillation or second/third-degree AV block) causing hemodynamic compromise
* Implantable pacemaker or other cardiac device with complete ventricular pacing
* Uncontrolled heart failure with hemodynamic compromise
* Uncontrolled hypertension (Systolic Blood Pressure \>150 mmHg and Diastolic Blood Pressure \>100 mmHg on repeated measurements)
* Active infection, anaemia, severe renal dysfunction (estimated Glomerular filtration rate \<30 ml/min/1,73m2) likely to significantly impact on exercise performance
* In some cases: use of anticoagulants or anti platelet therapy (see study procedure)

Healthy controls:

* All abovementioned exclusion criteria for FD patients
* History of smoking
* History of active drug use which can affect exercise intolerance
* History of asthma, chronic obstructive pulmonary disease, heart failure, heart surgery, heart rhythm disorders or congenital heart diseases
* Use of chronic medication likely to affect exercise tolerance
* Chronic illness (including orthopaedic, endocrinological, haematological, malignant, gastrointestinal, neurological, muscle or inflammatory disorders) likely to significantly impact on exercise performance
* \>6 alcohol units per day or \>14 alcohol units per week
```

## Arms

- **Men with classical Fabry disease**
- **Women with classical Fabry disease**
- **Men with non-classical Fabry disease**
- **Healthy controls** — Age-, Sex-, BMI-matched controls

## Interventions

- **Intermittent cardiopulmonary exercise test** (OTHER) — Exercise test with step-change from rest to a relatively low constant workload.
- **Incremental cardiopulmonary exercise test** (OTHER) — Exercise test with incremental workload until maximal workload.

## Primary Outcomes

- **Differences in V'O2 max kinetics (ml/kg/min)** _(time frame: At rest (baseline) and after maximum CPX test (30 min))_
- **Tiffeneau-index (FEV1/IVC ratio)** _(time frame: At rest (baseline))_ — Pulmonary involvement
- **Anaerobic threshold (ml/kg/min)** _(time frame: During maximum exercise (max 30 min).)_ — Pulmonary involvement/Cardiac dysfunction/Skeletal muscle alterations
- **Ventilation reserve (L)** _(time frame: During maximum exercise (max 30 min).)_ — Pulmonary involvement/Skeletal muscle alterations
- **CO2 ventilation equivalent (L/L)** _(time frame: During maximum exercise (max 30 min).)_ — Pulmonary involvement/Cardiac dysfunction
- **O2 saturation (%)** _(time frame: During maximum exercise (max 30 min).)_ — Pulmonary involvement/Cardiac dysfunction
- **Cardiac Output (L/min)** _(time frame: During maximum exercise (max 30 min).)_ — Cardiac dysfunction
- **Heart rate reserve (per minute)** _(time frame: During maximum exercise (max 30 min).)_ — Cardiac dysfunction:
- **Muscle size on echography (cm)** _(time frame: Baseline)_ — Skeletal muscle alterations
- **Muscle strength via resistance test (kg)** _(time frame: Biopsy at baseline)_ — Skeletal muscle alterations
- **Lipidomics profile of muscle tissue** _(time frame: Biopsy at baseline)_ — Skeletal muscle alterations
- **Electronic microscopic characteristics of muscle tissue** _(time frame: Biopsy at baseline)_ — Skeletal muscle alterations
- **Mitochondrial function of muscle tissue** _(time frame: Biopsy at baseline)_ — Skeletal muscle alterations

## Secondary Outcomes

- **Correlation between V'O2 kinetics during intermittent exercise and V'O2 max on the incremental maximum CPX (Pearson correlation coefficient).** _(time frame: Day 1)_
- **Correlation between V'O2 kinetics during intermittent exercise and activity score on the SQUASH Questionnaire (Pearson correlation coefficient).** _(time frame: Day 1)_
- **Correlation between V'O2 kinetics during intermittent exercise and functional and morphological cardiac parameters on cardiac imaging (Magnetic resonance or echocardiography) (Pearson correlation coefficient).** _(time frame: Day 1)_

## Locations (1)

- Amsterdam UMC, location AMC, Amsterdam, Netherlands — _RECRUITING_

## Recent Field Changes (last 30 days)

- `sponsor.lead` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.amsterdam umc, location amc|amsterdam||netherlands` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05413876.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05413876*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*